Dermatology Times' Sunday Crossword: May 4, 2025

Welcome to Dermatology Times' Sunday Crossword, where dermatology knowledge meets fun! Each week, we curate a selection of words and terms pulled directly from the latest news in the dermatology world. Whether it's breakthrough treatments, new research findings, or emerging trends, this crossword serves as both a challenge and an opportunity to reinforce your expertise in the field.

For more in-depth insights, don't forget to check out our Weekly Roundup, where we break down the most important stories and updates from the past week. And to stay ahead of the curve and prepare for future crosswords, make sure to follow our content throughout the week.

Try out either our interactive crossword or a static/non-interactive version below.

Interactive Crossword

This crossword was created with CrosswordLabs.com.

Static/Non-Interactive Crossword

Across

3. A recent article highlighted the long-term psychosocial burden experienced by survivors of this late-stage skin cancer.

5. Targeting this receptor may enhance next-generation eczema therapies by acting upstream of cytokines.

6. Q32 Bio’s investigational drug received FDA Fast Track designation for treating alopecia areata.

8. Along with botulinum toxin A, this substance helped improve skin texture by reducing acne-related pores.

10. This diagnostic test outperformed CP-GEP in identifying patients who may safely skip sentinel lymph node biopsy.

11. Multimodal imaging found that this structural protein varies depending on the phenotype of skin photoaging.

Down

1. This IL-23 inhibitor showed high effectiveness in treating moderate to severe plaque psoriasis in a Korean real-world study.

2. Two dosing regimens of this oral retinoid were explored for treating recalcitrant facial flat warts.

4. OCT and D-OCT imaging revealed distinct patterns in this type of skin damage caused by chronic sun exposure.

7. This non-invasive physical stimulus was shown to enhance wound healing and tissue regrowth.

9. This gene therapy became the first FDA-approved treatment for recessive dystrophic epidermolysis bullosa.

12. (Abbreviation) The "Hats On" campaign raises awareness for this precancerous skin condition.

For answers to this week's puzzle, check out next week's edition of the Dermatology Times Sunday Crossword.

Answers from our April 20, 2025 puzzle: [Across: 2 - sequencing; 4 - zabalafin; 7 - Codex; 9 - RAD; 10 - sleep; 11 - upadacitinib; 12 - vitamins; 13 - burden; Down: 1 - inflammation; 3 - pruritus; 5 - ruxolitinib; 6 - tapinarof; 8 - dupilumab]